Transcutaneous Electrical Acupuncture Stimulation (TEAS) for gastrointestinal dysfunction in adults undergoing abdominal surgery: study protocol for a prospective randomized controlled trial

CURRENT STATUS: UNDER REVISION

Ya-Fan Bai
Capital Medical University Affiliated Beijing Friendship Hospital

ORCiD: https://orcid.org/0000-0003-2449-4909

Chao Gao
Beijing Huiming Hospital

Wen-Jing Li
Capital Medical University Affiliated Beijing Friendship Hospital

Yi Du
Department of Traditional Chinese, Beijing Friendship Hospital

Li-Xin An
Department of Anesthesiology, Beijing Friendship Hospital

anlixin8120@163.com Corresponding Author
ORCiD: https://orcid.org/0000-0001-6344-4010

DOI:
10.21203/rs.3.rs-19311/v2

SUBJECT AREAS
Anesthesiology & Pain Medicine Gastroenterology & Hepatology

KEYWORDS
TEAS, Postoperative gastrointestinal function, Randomized controlled trials, Protocol
Abstract
Background: Postoperative gastrointestinal (GI) dysfunction (PGD) is a common problem after abdominal surgery. PGD can increase the length of hospital stay and may lead to serious complications. Acupuncture and moxibustion are alternative therapies for PGD that have been used in some settings. However, the effect of preventive application of acupuncture or transcutaneous electrical acupuncture stimulation (TEAS) is still uncertain. The purpose of this study is to investigate the efficacy of the continuous application of TEAS on GI function recovery in adults undergoing abdominal surgery. At the same time, we will try to confirm the mechanism of TEAS through the brain-gut axis.

Methods/design: This study is a prospective, single-center, two-arm, randomized controlled trial that will be performed in a general hospital. In total, 280 patients undergoing abdominal surgery were stratified by type of surgery (i.e., gastric or colorectal procedure) and randomized into two treatment groups. The experimental group will receive TEAS stimulation at L14 and PC6, ST36 and ST37. The sham group will receive pseudo-TEAS at sham acupoints. The primary outcome will be the recovery time of postoperative bowel sounds, flatus, bowel movements and the changes in perioperative brain-intestinal peptides. The secondary outcome will be postoperative pain, perioperative complications, and hospitalization duration.

Discussion: The results of this study will demonstrate that continuous preventive application of TEAS can improve the GI function recovery in patients undergoing abdominal surgery and that this effect may act through brain-gut peptides.

1. Introduction
Postoperative gastrointestinal dysfunction (PGD) refers to a series of clinical syndromes in which digestive tract symptoms are the main manifestation after a surgical operation. The most common postoperative syndromes affect the gastric, intestinal and biliary tract systems, and patients often experience symptoms such as abdominal distension, constipation, nausea and vomiting, and defecation disorders. The incidence of PGD can be as high as 10%-30% \[1, 2\]. Despite ongoing research and different new drug treatments, the incidence of abdominal distention within 24 h of an
operation is 8-28% of all surgeries\textsuperscript{[3]}. Patients with PGD have a longer duration of hospitalization, heavier economic burdens, and a much higher risk of serious complications, such as infection, electrolyte disturbances, and even life-threatening conditions\textsuperscript{[3-5]}. Therefore, for postoperative patients in the hospital, restoring the normal function of the gastrointestinal (GI) tract as soon as possible for postoperative rehabilitation is a very important step.

Once PGD appears, the main treatment measures that can be taken include the use of gastric dynamics promoting drug, GI decompression, nutritional support, nonsteroidal anti-inflammatory drug treatments and so on\textsuperscript{[2,6]}. However, the therapeutic effect of these treatments is limited, and the patients’ satisfaction rate is relatively low\textsuperscript{[6]}. Currently, many studies have demonstrated that acupuncture and moxibustion have unique advantages in the treatment of PGD\textsuperscript{[7]} and have gradually obtained more acceptance from physicians as an alternative therapy.

Recently, brain-gut axis, serving as a bridge between the central nervous system (CNS) and the GI tract\textsuperscript{[8,9]}, has been proved to be one of the possible mechanisms of acupuncture improving GI. Through the brain-gut axis, signals from the brain affect the sensory, motor, and endocrine modalities, as well as the microflora of the GI gut. Similarly, visceral information from the microbiota may also influence brain functions\textsuperscript{[8]}. In our previous studies, our research group also found that electroacupuncture stimulation of Zusanli (ST36) could lead to imaging changes in different brain regions observed by functional magnetic resonance imaging (fMRI)\textsuperscript{[10]}. These results demonstrated that acupuncture may act through the brain-gut axis. Brain-gut peptides are distributed along the GI tract and in the CNS and are involved in the modulation of GI tract processing\textsuperscript{[11]}. The secretion of substance P (SP) and vasoactive intestinal polypeptide (VIP) are decreased, motilin and cholecystokinin (CCK) are increased after treatment with EA in rats with irritable bowel syndrome (IBS)\textsuperscript{[12,13]}. However, until now, most research on this mechanism has focused on animal studies and the treatment effect of acupuncture or TEAS on patients after abdominal surgery\textsuperscript{[\textbullet]} whether the prevention effect of TEAS on PGD through brain-gut peptides or not is still unclear.
Based on previous studies, our aim is to confirm the preventive effect of TEAS on PGD in patients undergoing abdominal surgery. Changes in the perioperative brain-gut peptides may prove that the regulation of GI function by TEAS stimulation plays a role through the brain-intestinal axis. Health economic indicators (length of stay, cost of hospitalization, etc.), will also demonstrate the significance of perioperative TEAS stimulation on postoperative GI function recovery of patients undergoing abdominal surgery. This study will provide further evidence as to whether TEAS should be included in enhanced recovery after surgery (ERAS) protocols for patients undergoing GI surgery.

2. Methods

The protocol for this trial is reported based on the Standard Protocol Items: Recommendations for Interventionsal Trials (SPIRIT) 2013 Checklist: defining standard protocol items for clinical trials (Additional file 1). The study has been approved by the Ethics Committee of Beijing Friendship Hospital (the approval number from the Ethics Committee is 2019-P-065-01) and has been registered in the Chinese Clinical Trial Registry (Chictr) (registration number: ChiCTR1900023263). And this study is still in process.

2.1 Trial design

The trial is a single-center, prospective, randomized controlled trial (RCT) with a two-arm, parallel-group design (Fig. 1). Data analysis will be performed according to the superiority principle. The study will be carried out at Beijing Friendship Hospital and will be performed according to the principles of the Declaration of Helsinki (version Edinburgh 2000).

Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram for this trial.

The study will continue for 24 months, and all the selected subjects will be stratified by type of surgery (i.e., gastric or colorectal procedure) and randomized into two groups: the TEAS treatment group (Group T) and the sham group (Group S). The researchers will conduct screening in accordance with the established criteria and prestandard treatment plan. The data collection will start from the collection of basic data until the end of follow-up (Table. 1).

Table 1. Standard Protocol Items: Recommendations for Interventionsal Trials (SPIRIT) Schedule for enrollment, interventions, and assessments
|                  | The day before the surgery | The surgery day | 1 | 2 | 3 | 4 | N | Out of the hospital |
|------------------|----------------------------|----------------|---|---|---|---|---|-------------------|
| Enrollment       |                            |                |   |   |   |   |   |                   |
| Enrollment       | x                          |                |   |   |   |   |   |                   |
| Informed consent | x                          |                |   |   |   |   |   |                   |
| Allocation       | x                          |                |   |   |   |   |   |                   |
| Interventions    |                            |                |   |   |   |   |   |                   |
| Intervention     | x                          |                | x | x | x | x |     |                   |
| Laboratory       |                            |                |   |   |   |   |   |                   |
| Blood            |                            |                |   |   |   |   | x |                   |
| Assessments      |                            |                |   |   |   |   |   |                   |
| The baseline indicators | x |                |   |   |   |   |     |                   |
| Intraoperative situation | x |                |   |   |   |   |     |                   |
| Exhaust time     |                            |                |   |   |   |   |   |                   |
| Bowel sounds time|                            |                |   |   |   |   |   |                   |
| Defecation time  |                            |                |   |   |   |   |   |                   |
| Solid food time  |                            |                |   |   |   |   |   |                   |
| Nausea and vomiting |                        |                |   |   |   |   |   |                   |
| Pain score       |                            |                |   |   |   |   |   |                   |
| Health economics |                            |                |   |   |   |   | x |                   |
2.2 Randomization and blinding

This is a single blinded study. The doctors from the traditional Chinese department who will conduct the TEAS stimulation and the anesthesiologists will know the grouping information, participants. The observers of major outcomes after surgery will be blinded. Randomization will be conducted by a computer-generated blocked randomization list with 70 blocks of four patients per block. The participants will be consecutively randomly assigned to the TEAS group or the sham group at a ratio of 1:1. Allocation shall proceed via duplicate, sealed, numbered envelopes, which will be stored by the clinical trial quality control inspectors and the main person in charge of this research group. The blind bottom shall not be opened without reason during the trial. The outcome assessors and the statisticians will not participate in the treatment, they will perform the outcome evaluation and the statistical analysis independently.

2.3 Study participants and recruitment

We will recruit 280 patients scheduled to undergo laparoscopic resection of gastric and colorectal tumors. These patients will be recruited from Beijing Friendship Hospital affiliated with Capital Medical University after they meet the eligibility criteria and sign their informed consent. We plan to enroll the first patient on July 1, 2019 and to end on December 31, 2020. All participants will sign the informed consent form for participating in the clinical trial and the informed consent form for collecting blood samples.

2.3.1 Inclusion criteria include the following: ① 18-70 years old, regardless of gender; ② undergoing endotracheal intubation and laparoscopic abdominal tumor resection under general anesthesia (stomach, colon and rectum); ③ $18 \leq \text{BMI} \leq 30 \text{ kg/m}^2 \quad \text{[body mass index = weight (kg)/height (m)}^2]; \quad \text{⑤}\text{American Society of Anesthesiologists (ASA) classification that is level I-III; } \text{⑥ requirement for a postoperative analgesia pump and signing of informed consent; } \text{⑥volunteering to participate in this study and sign the informed consent.}

2.3.2 Exclusion criteria include the following: ① surgical incision or scar on the meridian of L14/ PC6/ ST36/ ST37; ② local skin infection at acupoints; ③ upper limb or lower limb nerve injury; ④ a history of spinal surgery; ⑤ participation in other clinical trials within the past four weeks; ⑥ inability to understand the visual analog scale (VAS) score and numeric rating scale (NRS) score or to use patient-controlled analgesia (PCA); ⑦ presence of a pacemaker; ⑧ preoperative complications involving severe CNS diseases or severe mental diseases; ⑨ operations requiring enterostomy or
conversion to open surgery; necessity of transfer to the ICU for treatment after surgery.

2.3.3 Discharge criteria are as follows: (1) requirement for subjects to withdraw during the test; (2) violation of the test program; (3) occurrence of serious adverse events.

2.4 Interventions

Patients receiving TEAS treatment will be treated bilaterally at four acupoints: Hegu (L14) and Neiguan (PC6), as well as Zusanli (ST36) and Shangjuxu (ST37). L14 is an acupoint of the hand yangming large intestine meridian. It is located on the dorsum of the hand between the first and second metacarpal bones (Fig.2). PC6 belongs to the pericardium meridian. It is located between the flexor carpi radialis muscle tendon and the palmaris longus tendon, 2 cun above the rasceta (Fig.2). ST36 and ST37 are acupoints of the foot yangming stomach meridian. ST36 is located on the lateral side of the lower leg, 3 cun below Dubi and one finger width lateral to the anterior border of the tibia (Fig. 3). ST37 is located 3 cuns below ST36. An electrode with wire will be attached to the site of these acupoints. The wire is connected to the HANS acupoint nerve stimulator (HANS-200A, Nanjing Jisheng Medical Technology Co., Ltd., China). TEAS stimulation uses a dense-dispersed wave with frequencies of 2 and 100 Hz alternating every 3 s. The waveform is a symmetric biphasic curve. The stimulation intensity will be set to the level of maximum tolerance for each patient. During the operation, the TEAS stimulation will span from before the induction to the end of the operation. On the 1st, 2nd, and 3rd day after surgery, the acupuncture doctor will arrive at the ward in the morning at 9 am to administer TEAS stimulation at the same acupoints for 30 min. This stimulation will be continued until the patients’ flatus recovery.

Figure 2. The location of L14, PC6. L14 is Hegu acupoint; PC6 is Neiguan acupoint.

Figure 3. The location of ST36, ST37. ST36 is Zusanli acupoint; ST37 is Shangjuxu acupoint.

In the sham group, the sham points are at 7 cun and 9 cun above Shenmen (HT7) and outside 1 cun (Fig.4). The other two sham points are at 9 and 12 cun above the Kunlun (BL60) (Fig.5). There are no meridian and channels through these four sites, and thus we will use these positions as our sham points. We will put the electrode on the sham points and connect it to the HANS stimulator but not administer any stimulation. The same doctor will go to the ward, put the electrode on these points and connect it to the stimulator (not open) at the same time after surgery, until the first flatus recovery.

Figure 4. The location of sham point 1 and 2. HT7 is Shenmen acupoint. Cun is the length unit.

Figure 5. The location of sham point 3 and 4. BL60 is Kunlun acupoint. Cun is the length unit.
The anesthesia is total intravenous anesthesia, no epidural, paravertebral block, TAP or other nerve block is added during the operation. Before the end of the operation, 0.5% ropivacaine incision infiltration block will be performed in the incision of endoscope. The general anesthesia drugs and methods during the operation are determined by the chief anesthesiologist and conform to the treatment routine and work habits.

Postoperative analgesia measures and remedial plan: The analgesic pump configuration: after the operation, the intravenous analgesic pump (PCIA) was connected, and the analgesic formula sufentanil 250ug was added with normal saline to 250ml, 2ml/h, and PCA 3ml at an interval of 15min.①Analgesia recovery: subjects were given Flubiprofen 50 mg/ivgtt in the ward when the pain VAS score was ≥4 points and the pain score was still ≥4 points after 5 consecutive effective PCA compressions.②Remedy of nausea and vomiting: NRS method was used for nausea score. When nausea score ≥7 points or vomiting ≥1time, serotonin 3 receptor antagonist was given. The remedial medication should be recorded in the remedial medication list.③Concomitant medication record: concomitant medication during the trial period (from the start of surgery to 5 days after the end of surgery).

2.5 Outcome assessment

A blind observer from the data monitoring committee will collect all outcome data after surgery. The primary outcomes of this study will be time to first bowel motion, time to fist flatus and time to defecation. This information will be obtained from participant questionnaires filled out once daily with the help of nurse staff. The same surgical residents will listen to the bowel sounds every 4 h postoperatively. Time to first bowel motion is the duration until regular bowel sounds (more than two sounds every minute) are first heard after surgery [17]. To observe changes in plasma brain-gut peptides, such as 5-HT, SP, VIP, gastrin and CCK, we will collect venous blood from patients before the operation and 1st day and 3rd day after the operation and then will centrifuge and freeze the plasma supernatant for later testing. We cooperate with our clinical experimental center to collect, code, centrifuge, freeze store, store and test blood samples by a professional team.

Secondary endpoints will include the time to defecation, VAS score of postoperative pain, vomitting and nausea, length of stay in the intensive care unit (ICU), length of stay in the hospital, and cost of stay in the hospital, as well as clinical complications such as fever, pneumonia, wound infection and bleeding. Secondary outcome will be assessed by the medical team. The length of hospital stay is calculated as the number of days from the date of the operation to the date of discharge. Criteria for hospital discharge will include stable vital signs, the ability to tolerate solid foods after defecation without nausea or vomiting, and the occurrence of no other complications after
the operation.

2.6 **Sample size calculation**

Due to a lack of related reports on the preventive usage of TEAS in patients undergoing GI surgery, we evaluated the effectiveness of TEAS according to our pre-experimental results. A priority-effectiveness test was used, and the ratio between the groups was 1:1. According to the pre-experimental results, a difference in time to first bowel sounds of 12 hours was thought to be clinically significant and selected as the effect size. This result in a hazard ration of 1.5. The COX regression sample size calculation formula was used to complete the sample size estimation. We set unilateral \( \alpha = 0.05 \), power = 0.90, PASS 2011 software was used for sample estimation, and a total of 256 effective cases were estimated. According to the above sample estimation result and assuming 10% patient loss, a minimum of 280 cases is required. Therefore, we have set the required number of cases in this study to 280 cases, including 140 cases in the TEAS group and 140 cases in the sham TEAS group. Our General Surgery Department performs 400-500 cases of GI surgery per year, and consequently, this study period is set at 2 years.

**Statistical methods**

Statisticians are responsible for negotiating with major researchers to develop statistical analysis plans, establish databases, and conduct statistics with the SPSS statistical analysis system. All data will be collated by statisticians. The intention processing principle in SPSS 22.0 will be used for the data analysis. A unilateral test will be used for statistical results, and a \( P \) value < 0.05 will be considered statistically significant. The results will be expressed as the mean ± standard deviation. The t-test will be used for the normality and homogeneity of data, the hypothesis test of superiority will be used for major outcome indicators, the chi-square test will be used for normal distribution data, and the rank sum test or Fisher exact probability method will be used for non-normal distribution data. Statistical methods for the main efficacy indicators have been determined by the Capital Medical University statistical department.

2.8 **Data collection methods and monitoring**

The statistical professionals are responsible for formulating the statistical analysis plan through consultation with the main researchers, establishing the database, and using the SPSS statistical analysis system for statistics. A comprehensive efficacy analysis was conducted in accordance with the program set, and the whole analysis set, demographic and other baseline characteristics, and other efficacy indicators were analyzed in accordance with the program set.

The Data Monitoring Committee (DMC) is consisting by a doctor in charge of data collection and
sorting, a scientific research manager and a statistician. Doctor from DMC will record the actual number of subjects enrolled, the cases of exclusion, demographic and other baseline characteristics, compliance analysis, safety analysis, incidence of complications and combined treatment, and comprehensive efficacy evaluation. The demographic characteristics, medical history and treatment history of the patients will be described, including the comparison of age, gender, disease course and disease condition at the time of enrollment. The scientific research management committee will have access to the final trial dataset. At the end of the study, the original data and results will be submitted to the scientific research management committee, and they will be disclosed to the public after the results are published.

2.9 Safety evaluation

Adverse events (AEs) are the appearance or progression of any symptoms of discomfort, syndromes or diseases that occur during a clinical trial and affect the health of the subject. Any abnormalities in clinical testing that indicate the presence of disease and/or organ toxicity and serious abnormalities requiring active treatment (such as withdrawal of medication, increased follow-up, and diagnostic studies) are considered AEs. In the process of clinical research, researchers should fill in the AEs record form truthfully and in detail, recording the clinical manifestations, occurrence time, severity, duration, measures taken and outcomes of AEs.

When an AE occurs, the observing physician may decide whether to suspend the observation or not according to the condition. All AEs should be tracked and documented in detail until the subject is properly resolved or is in stable condition, and if laboratory tests are abnormal and clinically significant, they should be tracked back to pretreatment levels.

3. Discussion

PGD comprises the most common series of clinical syndromes with digestive symptoms as the main manifestation after surgery and is commonly seen after abdominal surgery; the delay of flatus and defecation is often the first sign of PGD in patients \([1,2]\). The application of traditional Western medicine has corresponding defects, and the results are often unsatisfactory \([6]\). According to the theory of traditional Chinese medicine, PGD is one of the diseases of "intestinal bi" and "intestinal knot". Abdominal surgical injury and meridian blood vessels, blood stasis to block intestinal fu, intestinal fu internal turbid qi stasis, and tangible evil obstruction result in fu-qi obstruction. After the operation, qi and blood deficiency, adverse transport, GI function loss, plus surgery and injury and flesh muscles and bones result in bleeding outside the vein, block qi, and cause abdominal pain,
abdominal distension, nausea, vomiting and a series of symptoms.

A large number of previous clinical studies and animal experiments have confirmed that the effect of electroacupuncture and TEAS can improve postoperative GI disorders [14, 15]. Electrical stimulation of Zusanli can activate vagus nerve fibers by a spinal cord reflex and promote gastric motility [16].

Similarly, it has been reported by Iwa [17] et al. that the application of EA in rats with conscious free movement may promote distal colon movement and accelerate colon transport through the sacral efferent parasympathetic pathway. EA may help repair damage to the GI barrier by regulating the neuroendocrine immune system and fighting inflammation [18]. EA stimulation of Zusanli and other acupoints can play a protective role in intestinal injury and mucosal barrier dysfunction of rats with blood loss by activating cholinergic anti-inflammatory pathways and intestinal glial cells (known to secrete epidermal growth factor, thereby increasing the recovery rate of epithelial cells) [19-21].

In recent years, research on the brain-gut axis has become a hot topic. The brain affects the sensation, movement, endocrine and microflora of the GI tract through the brain-gut axis. Gut information from the microbiome may also affect brain function [8, 9, 22]. Brain-gut peptide, regulation of the vagus nerve and nerve excitability of the posterior horn of the spinal cord are all possible mechanisms of the brain-gut axis regulating GI function [23]. Brain-gut interaction is achieved by a variety of substances in the endocrine cells of the CNS, neuroendocrine system and GI tract, which act as neurotransmitters and hormones at the same time and are called brain-gut peptides [24]. Brain-gut peptides widely regulate GI activity and are therefore closely associated with PGD. Major excitatory neurotransmitters include histamine, 5-HT, SP, calcitonin gene-related peptide (CGRP) and adrenocorticotropic releasing factor-related peptide (CRF). Major inhibitory neurotransmitters include cholecystokinin (CCK), nitric oxide (NO), norepinephrine (NE) and VIP [25]. Clinical studies have confirmed that the contents of 5-HT in the intestinal mucosa of patients with GI dysfunction are significantly increased. Other studies have found that EA can regulate the secretion of SP, SP receptor and VIP in the IBS model colon [26]. CRF can induce repeated defecation in rats. Both sets of findings
have confirmed the possible role of brain-gut peptides in patients with GI dysfunction [27].

Although the clinical therapeutic effect of electroacupuncture on GI dysfunction has been confirmed by many investigations, the role of preventive acupuncture treatment of perioperative patients, especially high-risk patients (receiving abdominal surgery), and the mechanism of this role associated with the brain-intestinal tract have not been confirmed by any clinical studies and still need to be verified by much research.

However, some limitations in this study should be noted. First, the main outcome measures are subjective evaluation scales that lack objective evidence to directly support the effect of a given treatment. Second, after completion of the 6-week treatment, a 3-month follow-up will be conducted, and the dropout rate may be higher. To minimize potential dropouts, we have established guidelines and training for research staff to establish good communication relationships with the participants.

In conclusion, the results of this methodologically rigorous trial are expected to provide not only clinical evidence of the effectiveness and safety of TEAS on GI function in patients after abdominal surgery but also demonstrate the mechanism of TEAS treatment on GI function.

**Trial Status**

The first participant was enrolled on September 1, 2019, and the first version was developed on August 20, 2019. The recruitment will be completed on December 31, 2020. Shown above is the third version whose protocol was revised for the following reasons: unspecific statistical methods; imprecise sample size calculation; and inappropriate descriptions. To date, 106 participants have been recruited. This trial is still ongoing.

**Additional File Information**

Additional file 1: Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Checklist.

**Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| PGD          | Postoperative gastrointestinal dysfunction |
| TEAS         | Transcutaneous electrical acupuncture stimulation |
| GI           | Gastrointestinal |
| CNS          | Central nervous system |
| SP           | Substance P |
| VIP          | Vasoactive intestinal polypeptide |
| CCK          | Cholecystokinin |
| IBS          | Irritable bowel syndrome |
| ERAS         | Enhanced recovery after surgery |
| DMC          | The Data Monitoring Committee |
| AEs          | Adverse events |
Declarations

**Ethics approval and consent to participate**

This study protocol and informed consent materials have been approved by the Ethics Committee of Beijing Friendship Hospital of TCM; Ethics Committee approval number: 2019-P-065-01. Written, informed consent to participate will be obtained from all participants.

**Consent for publication**

Not applicable.

**Availability of data and materials**

After the study is completed, the data will be open to the public through the Research Manager (ResMan) platform (http://www.medresman.org/login.aspx) within 6 months.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study has not received either external or internal funding.

**Authors’ contributions**

ALX is responsible for quality control of the topic selection, design, project implementation and paper revision; BYF is responsible for the performing of this study and the writing of this manuscript; GC and LWJ is responsible for clinical anesthesia and case collection; DY is responsible for acupuncture points teaching and TEAS manipulation. All authors read and approved the final manuscript.

**Acknowledgments**

I would like to express my sincere thanks to the Beijing Friendship Hospital, Capital Medical University. The authors will acknowledge all the participants in this study.

**References**

1. Short V, Herbert G, Perry R, et al. Chewing gum for postoperative recovery of gastrointestinal function. Cochrane Database Syst Rev. 2015; 20(2): 566-70.

2. Bragg D, El-Sharkawy AM, Psaltis E, et al. Postoperative ileus: Recent developments in pathophysiology and management. Clin Nutr. 2015; 34(3): 367-76.
3. Topcu SY, Oztekin SD. Effect of gum chewing on reducing postoperative ileus and recovery after colorectal surgery: A randomised controlled trial. Complement Ther Clin Pract. 2016; 23: 21-5.

4. Van den Heijkant TC, Costes LM, Van der Lee DG, et al. Randomized clinical trial of the effect of gum chewing on postoperative ileus and inflammation in colorectal surgery. Br J Surg. 2015; 102: 202-11.

5. Gan TJ, Robinson Sb, Oderda GM, et al. Impact of postsurgical opioid use and ileus on economic outcomes in gastrointestinal surgeries. Curr Med Res Opin. 2015; 31: 677-86.

6. Gustafsson UO, Scott MJ, Schwenk W, et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations. World J Surg. 2013; 37: 259-84.

7. Liu Y, May BH, Zhang AL, et al. Acupuncture and Related Therapies for Treatment of Postoperative Ileus in Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evid Based Complement Alternat Med. 2018; 29: 3178472.

8. Li H, He T, Xu Q, et al. Acupuncture and regulation of gastrointestinal function. World J Gastroenterol. 2015; 21(27): 8304-13.

9. Ma XP, Hong J, An CP, et al. Acupuncture-moxibustion in treating irritable bowel syndrome: how does it work? World J Gastroenterol. 2014; 20: 6044-54.

10. Cheng H, Zhang X, Bai L and Wang B. Differential temporal neural responses of pain-related regions by acupuncture at analgesia acupoint ST36: A MEG study. Chin Med J. 2011; 124(8): 1229-34.

11. Bonaz B, Sabate JM. Brain-gut axis dysfunction. Gastroenterol Clin Biol. 2009; 33: S48-S58.
12. Wu HG, Jiang B, Zhou EH, et al. Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion. Dig Dis Sci. 2008; 53: 1644-51.

13. Niu WX, He GD, Liu H, Qin XY. Effects and probable mechanisms of electroacupuncture at the Zusanli point on upper gastrointestinal motility in rabbits. J Gastroenterol Hepatol. 2007; 22: 1683-9.

14. Shin KM, Park JE, Lee S, et al. Effect of siguan acupuncture on gastrointestinal motility: a randomized, sham-controlled, crossover trial. Evid Based Complement Alternat Med. 2013; 2013: 918392. doi:10.1155/2013/918392.

15. Yang ZK, Wu ML, Xin JJ, et al. Manual acupuncture and laser acupuncture for autonomic regulations in rats: observation on heart rate variability and gastric motility. Evid Based Complement Alternat Med. 2013; 2013: 276320. doi:10.1155/2013/276320.

16. Chen JDZ, Ni M, Yin J. Electroacupuncture treatments for gut motility disorders. Neurogastroenterol Motil. 2018; 30(7): e13393. doi:10.1111/nmo.13393.

17. Iwa M, Nakade Y, Pappas TN, et al. Electroacupuncture elicits dual effects: stimulation of delayed gastric emptying and inhibition of accelerated colonic transit induced by restraint stress in rats. Dig Dis Sci. 2006; 51: 1493-1500.

18. Liang C, Wang K, Xu B, et al. Electroacupuncture at acupoint ST 37(Shangjuxu) improves function of the enteric nervous system in a novel mouse constipation model. BMC Complement Alternat Med. 2016; 16(1): 392.

19. Du MH, Luo HM, Hu S, et al. Electroacupuncture improves gut barrier dysfunction in prolonged hemorrhagic shock rats through vagus anti-inflammatory mechanism. World J Gastroenterol. 2013; 19: 5988-99.

20. Shi X, Zhong Y, Yao J, et al. The influence of zusanli and nonmeridian acupuncture
points on the survival rate and intestinal tissue features after fatal hemorrhagic shock in rats. Evid Based Complement Alternat Med. 2013; 2013: 750620.
doi:10.1155/2013/750620.

21. Hu S, Zhao ZK, Liu R, et al. Electroacupuncture activates enteric glial cells and protects the gut barrier in hemorrhaged rats. World J Gastroenterol. 2015; 21: 1468-78.

22. Zhu X, Han Y, Du J, et al. Microbiota-gut-brain axis and the central nervous system. Oncotarget. 2017; 8(32): 53829-38.

23. Martin CR, Osadchiy V, Kalani A, et al. The Brain-Gut-Microbiome Axis. Cell Mol Gastroenterol Hepatol. 2018; 6(2): 133-48.

24. Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Adv Exp Med Biol. 2014; 817: 195-219.

25. Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132: 397-41.

26. Yu YC, Li J, Zhang M, et al. Resveratrol Improves Brain-Gut Axis by Regulation of 5-HT-Dependent Signaling in the Rat Model of Irritable Bowel Syndrome. Front Cell Neurosci. 2019; 13: 30-7.

27. Han W, Tellez LA, Perkins MH, et al. A Neural Circuit for Gut-Induced Reward. Cell. 2018; 175: 1-14.

Figures
Figure 1

Consolidated Standards of Reporting Trials (CONSORT) diagram for this trial.
Figure 2

The location of L14, PC6. L14 is Hegu acupoint; PC6 is Neiguan acupoint.
Figure 3

The location of ST36, ST37. ST36 is Zusanli acupoint; ST37 is Shangjuxu acupoint.
Figure 4

The location of sham point 1 and 2. HT7 is Shenmen acupoint. Cun is the length unit.
The location of sham point 3 and 4. BL60 is Kunlun acupoint. Cun is the length unit.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
SPIRITChecklist.doc